The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Foreign investors buy UK firms at fastest pace since 2007

Tue, 24th Mar 2015 15:02

* UK acquisitions by foreign buyers total $48 bln year todate

* Highest since 2007 even if bid for O2 is excluded

* Weaker pound, better growth lure U.S. buyers

* Political uncertainty fails to dampen appetite

By Francesco Canepa

LONDON, March 24 (Reuters) - Foreign investors are snappingup British companies at the fastest pace in eight years as anunusual combination of stronger economic growth and a weakcurrency lures U.S. buyers despite political uncertainty.

Investors appear relatively unconcerned about the risk ofinstability after a general election on May 7 or doubts aboutBritain's future in the European Union. Even excluding a $15billion bid by Hutchison Whampoa for O2's UKoperations, inbound mergers & acquisitions activity so far thisyear is at its highest since 2007, Thomson Reuters data showed.

The total value of bids and completed deals in the period is$33 billion, including debt taken on by buyers. The figure risesto $48 billion when Hong Kong-based Hutchison's bid for themobile phone operator is included.

This reverses a seven-year decline and contrasts to a fallin inbound M&A activity in the euro zone and United States.

It also confounds expectations of dwindling M&A before theelections, in which opinion polls suggest no party will win amajority. This raises the possibility of an unstable coalitionor minority government propped up by smaller parties such as thepro-independence Scottish nationalists.

On top of this, the ruling Conservatives have promised areferendum within two years on whether Britain should leave theEU, should they be re-elected.

Many British business leaders are worried by the prospect.The chairman of insurer Standard Life said on Tuesday it would be disastrous for the country and London's financialcentre if Britain were to leave the EU single market.

However, bankers say U.S. investors are being attracted bysterling's weakness against the dollar - which makes Britishtargets cheaper for them - even though the economy is buoyant.

"The UK is at the forefront because the economy, aside fromthe uncertainty around the elections, is an attractive marketwith good growth dynamics," said Dirk Albersmeier, co-head ofM&A for Europe, the Middle East and Africa at JP Morgan.

With the Bank of England expected to keep interest ratesultra low for another year, the pound has fallen 13 percentagainst the dollar since July and is now hovering just above afive-year low. At the same time, official economic growthforecasts were upgraded last week to 2.5 percent this year and2.3 percent in 2016.

VALUATIONS BOOST

Valuations have provided a further boost. UK shares trade ata 10 percent discount to their U.S. counterparts based on theratio between price and expected earnings, Datastream datashowed.

Inbound M&A activity in Britain had been falling since 2007,data from the Office for National Statistics showed, partly dueto the pound's recovery against the euro since 2009.

This year's increase has been driven by 73 small andmid-sized acquisitions by U.S. buyers, such as drinks can makerBall Corp's $8.6 billion move for rival Rexam and a $2.8 billion bid by Verisk Analytics for energyconsultancy Wood Mackenzie.

These deals have more than offset a drying up of last year'sstream of large bids which were partly motivated by lowercorporate tax rates in Britain than in the United States, suchas Pfizer's abandoned attempt to buy fellowpharmaceutical group AstraZeneca.

Such bids have been curbed by a tightening of U.S. tax rulesand worries about possible fiscal changes in Britain after theelections.

As the economic recovery picks up pace, sectors which dependon growth are playing a larger role in M&A, joining defensivesectors such as healthcare and telecommunications, media andtechnology (TMT), where activity has been high for some time.

Aside from the telecoms and materials sectors, where theamount was skewed by the O2 and Rexam bids, inbound M&A activitythis year has been at its highest in the consumer goods sectorand industrial sectors, the data showed.

This marks a change from the previous year, when real estatedominated, with financials and high tech a distant second andthird, respectively.

"Activity is likely to be more broad-based than last year,"said Wilhelm Schulz, head of M&A for Europe, the Middle East andAfrica at Citi. "I expect this year we will see activity inhealthcare, TMT, industrials, chemicals and consumer products." (Additional reporting by Anjuli Davies and Freya Berry; editingby David Stamp)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.